Cambridge Investment Research Advisors
CUE icon

Cambridge Investment Research Advisors’s Cue Biopharma CUE Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-667
Closed -$5K – 4075
2026
Q1 		$5K Hold
667
– – ﹤0.01% 3915
2025
Q4 		$6K Hold
667
– – ﹤0.01% 3807
2025
Q3 		$14K Hold
667
– – ﹤0.01% 3699
2025
Q2 		$14K Hold
667
– – ﹤0.01% 3590
2025
Q1 		$18K Hold
667
– – ﹤0.01% 3461
2024
Q4 		$22K Hold
667
– – ﹤0.01% 3416
2024
Q3 		$15K Sell
667
-73
-10% -$1.58K ﹤0.01% 3379
2024
Q2 		$28K Hold
740
– – ﹤0.01% 3251
2024
Q1 		$42K Hold
740
– – ﹤0.01% 3228
2023
Q4 		$59K Hold
740
– – ﹤0.01% 3090
2023
Q3 		$51K Buy
740
+73
+11% +$7.13K ﹤0.01% 3040
2023
Q2 		$73K Buy
+667
New +$78.4K ﹤0.01% 3048

Other funds holding CUE

RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return
PWA
Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Cambridge Investment Research Advisors's CUE Position: Q2 2026 in Review

Cambridge Investment Research Advisors sold out of Cue Biopharma (CUE) in Q2 2026, closing a stake of 667 shares — an estimated $5K sold.

Cambridge Investment Research Advisors first reported a position in CUE in Q2 2023 and held it in 12 quarters. The position peaked at $73K in Q2 2023. 8 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • Cambridge Investment Research Advisors reported no remaining Cue Biopharma position as of Q2 2026 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 667 Cue Biopharma shares in Q2 2026, an estimated $5K.
  • Cambridge Investment Research Advisors first reported a position in Cue Biopharma in Q2 2023 and held it in 12 quarters.
  • Cambridge Investment Research Advisors's Cue Biopharma position peaked at $73K in Q2 2023.
  • 8 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.